Eroglu, Elif http://orcid.org/0000-0003-3952-3178
Yen, Christopher Y. T. http://orcid.org/0000-0001-5999-6306
Tsoi, Yat-Long http://orcid.org/0000-0002-8890-3989
Witman, Nevin http://orcid.org/0000-0002-1109-778X
Elewa, Ahmed
Joven Araus, Alberto http://orcid.org/0000-0002-0926-4665
Wang, Heng http://orcid.org/0000-0002-1727-9226
Szattler, Tamara http://orcid.org/0000-0002-1562-1278
Umeano, Chimezie H.
Sohlmér, Jesper http://orcid.org/0000-0003-2607-7500
Goedel, Alexander http://orcid.org/0000-0002-5980-2257
Simon, András http://orcid.org/0000-0002-1018-1891
Chien, Kenneth R. http://orcid.org/0000-0002-2759-8378
Article History
Received: 16 July 2021
Accepted: 21 March 2022
First Online: 12 May 2022
Competing interests
: K.R.C. is a scientific founder and equity holder in Moderna Therapeutics and Procella Therapeutics, and chair of the External Science Panel for AstraZeneca. The remaining authors declare no competing interests.